Marshall Wace’s Cellectis CLLS Stock Holding History

Marshall Wace’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$130K	Sell	41,112 -137,361	-77%	-$527K	﹤0.01%	2866
2025 Q4	$864K	Buy	178,473 +168,038	+1,610%	+$702K	﹤0.01%	2006
2025 Q3	$29.7K	Buy	+10,435	New	+$27K	﹤0.01%	2765
2022 Q4	–	Sell	-108,744	Closed	-$249K	–	2981
2022 Q3	$249K	Sell	108,744 -5,697	-5%	-$17.3K	﹤0.01%	3009
2022 Q2	$324K	Sell	114,441 -31,757	-22%	-$112K	﹤0.01%	2995
2022 Q1	$663K	Buy	146,198 +140,714	+2,566%	+$775K	﹤0.01%	2643
2021 Q4	$44K	Buy	+5,484	New	+$53.9K	﹤0.01%	3582
2020 Q3	–	Sell	-38,472	Closed	-$685K	–	1611
2020 Q2	$685K	Buy	+38,472	New	+$586K	﹤0.01%	1108
2019 Q4	–	Sell	-16,243	Closed	-$169K	–	1733
2019 Q3	$169K	Sell	16,243 -33,241	-67%	-$447K	﹤0.01%	1311
2019 Q2	$772K	Buy	+49,484	New	+$884K	0.01%	992

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Marshall Wace's CLLS Position: Q1 2026 in Review

Marshall Wace reduced its Cellectis (CLLS) stake by 77% in Q1 2026, selling an estimated $527K and leaving 41,112 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

Marshall Wace first reported a position in CLLS in Q2 2019 and has held it in 10 quarters since. The position peaked at $864K in Q4 2025. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

Marshall Wace held 41,112 shares of Cellectis worth $130K as of Q1 2026.
Marshall Wace sold 137,361 Cellectis shares in Q1 2026, an estimated $527K.
Cellectis made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2866 holding.
Marshall Wace first reported a position in Cellectis in Q2 2019 and has held it in 10 quarters since.
Marshall Wace's Cellectis position peaked at $864K in Q4 2025.
32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.